Client of a consultant lobbyist
RAREi - The Canadian Forum for Rare Disease Innovators
- Meetings this Parliament
- 1
- With MPs
- 1
- Since Nov 2021
- 19
- Active registrations
- 1
Most recent reported meeting: Apr 14, 2026.
Lobbying by RAREi - The Canadian Forum for Rare Disease Innovators: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
Consultant In effect since Oct 16, 2026
Consultant William Dempster of 3Sixty Public Affairs Inc.
Consultant lobbyists
-
William Dempster
Former public office holder
Formerly Assistant, Office of the Hon. Irwin Cotler, MP, House of Commons (2002–2003)
-
William Dempster
Former public office holder
Formerly Assistant, Office of the Hon. Irwin Cotler, MP, House of Commons (2002–2003)
-
William Dempster
Former public office holder
Formerly Assistant, Office of the Hon. Irwin Cotler, MP, House of Commons (2002–2003)
-
William Dempster
Former public office holder
Formerly Assistant, Office of the Hon. Irwin Cotler, MP, House of Commons (2002–2003)
Institutions they may lobby: Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Justice Canada (JC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Senate of Canada
What they're lobbying on (9)Hide details
- Enhancements related to intellectual property legislation, regulations and policies applicable to rare disease medicines.
- Issues related to U.S. pharmaceutical importation, trade and policies, including research and development, regulatory authorizations, funding of medicines, supply sources and supply chains.
- Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.
- Innovation, Science and Economic Development Canada regarding the Innovation and Skills Agenda and other government policies and programs related to incentivizing research and development activities in Canada, including the Biomanufacturing and Life Sciences Strategy.
- Regulations, guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board.
- Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.
- Federally-funded public drug plans, with respect to reimbursement for medicines for federal plan beneficiaries.
- Implementation of the Pharmacare Act and its implications for rare disease medicines.
- Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases.
Registration 778465-363257-21. Look it up in the official Registry
Reported meetings
Spreadsheet-
Reported by William Dempster · Consultant
- Dan Mazier · Member of Parliament
Innovation, Science and Economic Development Canada regarding the Innovation and Skills Agenda and other government policies and programs related to incentivizing research and development activities in Canada, including the Biomanufacturing and Life Sciences Strategy. Read more
Issues related to U.S. pharmaceutical importation, trade and policies, including research and development, regulatory authorizations, funding of medicines, supply sources and supply chains.
Enhancements related to intellectual property legislation, regulations and policies applicable to rare disease medicines.
Federally-funded public drug plans, with respect to reimbursement for medicines for federal plan beneficiaries.
Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.
Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases.
-
Reported by William Dempster · Consultant
- Stephen Ellis · Member of Parliament, House of Commons
Engagement with officials on issues related to the National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases. Read more
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with the Canadian Agency for Drugs and Technologies in Health (CADTH), Canada's Drug Agency and/or other pan-Canadian health organizations.
Regulatory amendments and/or guidelines and/or policies related to the Food and Drugs Act and Health Canada review of drugs for rare diseases.
nnovation, Science and Economic Development Canada regarding the Innovation and Skills Agenda, the Biomanufacturing and Life Sciences Strategy and other government policies and programs related to incentivizing research and development activities in Canada.
Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board.
Bill C-64: An Act respecting pharmacare, with a particular focus on access to medicines and rare disease and orphan drug policies
Federally-funded public drug plans, with respect to reimbursement for drug products for federal plan beneficiaries.
-
Reported by William Dempster · Consultant
- Guillaume Couillard · Executive Director, Patented Medicine Prices Review Board (PMPRB)
BudgetHealthIndustryResearch and DevelopmentScience and Technology
-
Reported by William Dempster · Consultant
- Andrew Cardozo · Senator, Senate of Canada
BudgetHealthIndustryResearch and DevelopmentScience and Technology
-
Reported by William Dempster · Consultant
- Judith Seidman · Senator, Senate of Canada
- Terri McGarry · Parliamentary Affairs Advisor, Senate of Canada
- Sylvie Clement · Director of Issues Management, Senate of Canada
BudgetHealthIndustryResearch and DevelopmentScience and Technology
-
Reported by William Dempster · Consultant
- Daniel MacDonald · Director General, Drugs for Rare Diseases, Health Canada (HC)
Economic DevelopmentHealthIndustry
-
Reported by William Dempster · Consultant
- Tom Kmiec · Member of Parliament
HealthIndustry
-
Reported by William Dempster · Consultant
- Guillaume Couillard · Executive Director, Patented Medicine Prices Review Board (PMPRB)
Health
-
Reported by William Dempster · Consultant
- Daniel MacDonald · Director General, Health Canada (HC)
Economic DevelopmentHealthIndustryScience and Technology
-
Reported by William Dempster · Consultant
- Majid Jowhari · Member of Parliament, House of Commons
Economic DevelopmentHealthIndustryIntellectual PropertyInternational TradeScience and TechnologyTaxation and Finance
-
Reported by William Dempster · Consultant
- Douglas Clark · Executive Director, Patented Medicine Prices Review Board (PMPRB)
Economic DevelopmentHealthIndustryIntellectual PropertyInternational TradeScience and TechnologyTaxation and Finance
-
Reported by William Dempster · Consultant
- Michelle Mujoomdar · Director, Health Canada (HC)
Economic DevelopmentHealthIndustryIntellectual PropertyInternational TradeScience and TechnologyTaxation and Finance
-
Reported by William Dempster · Consultant
- Tanya Potashnik · Director of Policy and Economic Analysis, Patented Medicine Prices Review Board (PMPRB)
Economic DevelopmentHealthIndustryIntellectual PropertyInternational TradeScience and TechnologyTaxation and Finance
-
Reported by William Dempster · Consultant
- Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
- Darryl Patterson · Director General, Innovation, Science and Economic Development Canada (ISED)
Economic DevelopmentHealthIndustryIntellectual PropertyInternational TradeScience and TechnologyTaxation and Finance
-
Reported by William Dempster · Consultant
- Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
Economic DevelopmentHealthIndustryIntellectual PropertyInternational TradeScience and TechnologyTaxation and Finance
-
Reported by William Dempster · Consultant
- Adam van Koeverden · Member of Parliament
Economic DevelopmentHealthIndustryIntellectual PropertyInternational TradeScience and TechnologyTaxation and Finance
-
Reported by William Dempster · Consultant
- Brent Lawlor · Director, Health Canada (HC)
Economic DevelopmentHealthIndustryIntellectual PropertyInternational TradeScience and TechnologyTaxation and Finance
-
Reported by William Dempster · Consultant
- Francesco Sorbara · Member of Parliment, House of Commons
Economic DevelopmentHealthIndustryIntellectual PropertyInternational TradeScience and TechnologyTaxation and Finance
-
Reported by William Dempster · Consultant
- Holly Duggan · Acting Manager of Stakeholder Relations, House of Commons
Economic DevelopmentHealthIndustryIntellectual PropertyInternational TradeScience and TechnologyTaxation and Finance
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.